Demographic and Clinical Characteristics of Study Participants at Study Entry
| Characteristic . | DTG + 3TC (n = 22) . | DTG + FTC/TAF (n = 22) . | Total (n = 44) . |
|---|---|---|---|
| Age, y, median (IQR) | 30.8 (27.7–35.2) | 33.5 (27.5–35.3) | 31.4 (27.3–35.4) |
| Male sex | 22 (100.0) | 22 (100.0) | 44 (100.0) |
| Ethnicity | |||
| White | 14 (63.6) | 12 (54.5) | 26 (59.1) |
| Hispanic/Latino | 8 (36.4) | 8 (36.4) | 16 (36.4) |
| Other | 0 (0.0) | 2 (9.1) | 2 (4.5) |
| BMI, kg/m2, median (IQR) | 24.2 (22.4–25.3) | 23.6 (21.2–24.8) | 23.9 (21.8–25.0) |
| Time from HIV acquisition <3 mo | 4 (18.2) | 4 (18.2) | 8 (18.2) |
| Transmission group: MSM | 19 (86.4) | 20 (90.9) | 39 (88.6) |
| pVL, copies/mL, median (IQR) | 27 101 (4794–59 467) | 48 392 (15 384–106 126) | 30 519 (8600–84 022) |
| pVL >105 log copies/mL | 3 (13.6) | 7 (31.8) | 10 (22.7) |
| HIV subtype | |||
| B | 19 (86.4) | 16 (72.7) | 35 (79.5) |
| C | 2 (9.1) | 1 (4.5) | 3 (6.8) |
| A1 | 0 | 1 (4.5) | 1 (2.3) |
| CRFs | 1 (4.5) | 3 (13.6) | 4 (9.1) |
| Not amplified | 0 | 1 (4.5) | 1 (2.3) |
| CD4+ T-cell count, cells/μL, median (IQR) | 497 (334–607) | 443 (367–528) | 455 (335–567) |
| CD4 <200 cells/μL | 0 (0.0) | 2 (9.1) | 2 (4.5) |
| CD4/CD8 ratio, median (IQR) | 0.5 (0.4–0.8) | 0.5 (0.4–0.8) | 0.5 (0.4–0.8) |
| Characteristic . | DTG + 3TC (n = 22) . | DTG + FTC/TAF (n = 22) . | Total (n = 44) . |
|---|---|---|---|
| Age, y, median (IQR) | 30.8 (27.7–35.2) | 33.5 (27.5–35.3) | 31.4 (27.3–35.4) |
| Male sex | 22 (100.0) | 22 (100.0) | 44 (100.0) |
| Ethnicity | |||
| White | 14 (63.6) | 12 (54.5) | 26 (59.1) |
| Hispanic/Latino | 8 (36.4) | 8 (36.4) | 16 (36.4) |
| Other | 0 (0.0) | 2 (9.1) | 2 (4.5) |
| BMI, kg/m2, median (IQR) | 24.2 (22.4–25.3) | 23.6 (21.2–24.8) | 23.9 (21.8–25.0) |
| Time from HIV acquisition <3 mo | 4 (18.2) | 4 (18.2) | 8 (18.2) |
| Transmission group: MSM | 19 (86.4) | 20 (90.9) | 39 (88.6) |
| pVL, copies/mL, median (IQR) | 27 101 (4794–59 467) | 48 392 (15 384–106 126) | 30 519 (8600–84 022) |
| pVL >105 log copies/mL | 3 (13.6) | 7 (31.8) | 10 (22.7) |
| HIV subtype | |||
| B | 19 (86.4) | 16 (72.7) | 35 (79.5) |
| C | 2 (9.1) | 1 (4.5) | 3 (6.8) |
| A1 | 0 | 1 (4.5) | 1 (2.3) |
| CRFs | 1 (4.5) | 3 (13.6) | 4 (9.1) |
| Not amplified | 0 | 1 (4.5) | 1 (2.3) |
| CD4+ T-cell count, cells/μL, median (IQR) | 497 (334–607) | 443 (367–528) | 455 (335–567) |
| CD4 <200 cells/μL | 0 (0.0) | 2 (9.1) | 2 (4.5) |
| CD4/CD8 ratio, median (IQR) | 0.5 (0.4–0.8) | 0.5 (0.4–0.8) | 0.5 (0.4–0.8) |
Data are expressed as No. (%) unless otherwise indicated.
Abbreviations: BMI, body mass index; CRFs, circulating recombinant forms; DTG + 3TC, dolutegravir plus lamivudine; DTG + FTC/TAF, dolutegravir plus emtricitabine/tenofovir alafenamide; HIV, human immunodeficiency virus; IQR, interquartile range; MSM, men who have sex with men; pVL, plasma viral load.
Demographic and Clinical Characteristics of Study Participants at Study Entry
| Characteristic . | DTG + 3TC (n = 22) . | DTG + FTC/TAF (n = 22) . | Total (n = 44) . |
|---|---|---|---|
| Age, y, median (IQR) | 30.8 (27.7–35.2) | 33.5 (27.5–35.3) | 31.4 (27.3–35.4) |
| Male sex | 22 (100.0) | 22 (100.0) | 44 (100.0) |
| Ethnicity | |||
| White | 14 (63.6) | 12 (54.5) | 26 (59.1) |
| Hispanic/Latino | 8 (36.4) | 8 (36.4) | 16 (36.4) |
| Other | 0 (0.0) | 2 (9.1) | 2 (4.5) |
| BMI, kg/m2, median (IQR) | 24.2 (22.4–25.3) | 23.6 (21.2–24.8) | 23.9 (21.8–25.0) |
| Time from HIV acquisition <3 mo | 4 (18.2) | 4 (18.2) | 8 (18.2) |
| Transmission group: MSM | 19 (86.4) | 20 (90.9) | 39 (88.6) |
| pVL, copies/mL, median (IQR) | 27 101 (4794–59 467) | 48 392 (15 384–106 126) | 30 519 (8600–84 022) |
| pVL >105 log copies/mL | 3 (13.6) | 7 (31.8) | 10 (22.7) |
| HIV subtype | |||
| B | 19 (86.4) | 16 (72.7) | 35 (79.5) |
| C | 2 (9.1) | 1 (4.5) | 3 (6.8) |
| A1 | 0 | 1 (4.5) | 1 (2.3) |
| CRFs | 1 (4.5) | 3 (13.6) | 4 (9.1) |
| Not amplified | 0 | 1 (4.5) | 1 (2.3) |
| CD4+ T-cell count, cells/μL, median (IQR) | 497 (334–607) | 443 (367–528) | 455 (335–567) |
| CD4 <200 cells/μL | 0 (0.0) | 2 (9.1) | 2 (4.5) |
| CD4/CD8 ratio, median (IQR) | 0.5 (0.4–0.8) | 0.5 (0.4–0.8) | 0.5 (0.4–0.8) |
| Characteristic . | DTG + 3TC (n = 22) . | DTG + FTC/TAF (n = 22) . | Total (n = 44) . |
|---|---|---|---|
| Age, y, median (IQR) | 30.8 (27.7–35.2) | 33.5 (27.5–35.3) | 31.4 (27.3–35.4) |
| Male sex | 22 (100.0) | 22 (100.0) | 44 (100.0) |
| Ethnicity | |||
| White | 14 (63.6) | 12 (54.5) | 26 (59.1) |
| Hispanic/Latino | 8 (36.4) | 8 (36.4) | 16 (36.4) |
| Other | 0 (0.0) | 2 (9.1) | 2 (4.5) |
| BMI, kg/m2, median (IQR) | 24.2 (22.4–25.3) | 23.6 (21.2–24.8) | 23.9 (21.8–25.0) |
| Time from HIV acquisition <3 mo | 4 (18.2) | 4 (18.2) | 8 (18.2) |
| Transmission group: MSM | 19 (86.4) | 20 (90.9) | 39 (88.6) |
| pVL, copies/mL, median (IQR) | 27 101 (4794–59 467) | 48 392 (15 384–106 126) | 30 519 (8600–84 022) |
| pVL >105 log copies/mL | 3 (13.6) | 7 (31.8) | 10 (22.7) |
| HIV subtype | |||
| B | 19 (86.4) | 16 (72.7) | 35 (79.5) |
| C | 2 (9.1) | 1 (4.5) | 3 (6.8) |
| A1 | 0 | 1 (4.5) | 1 (2.3) |
| CRFs | 1 (4.5) | 3 (13.6) | 4 (9.1) |
| Not amplified | 0 | 1 (4.5) | 1 (2.3) |
| CD4+ T-cell count, cells/μL, median (IQR) | 497 (334–607) | 443 (367–528) | 455 (335–567) |
| CD4 <200 cells/μL | 0 (0.0) | 2 (9.1) | 2 (4.5) |
| CD4/CD8 ratio, median (IQR) | 0.5 (0.4–0.8) | 0.5 (0.4–0.8) | 0.5 (0.4–0.8) |
Data are expressed as No. (%) unless otherwise indicated.
Abbreviations: BMI, body mass index; CRFs, circulating recombinant forms; DTG + 3TC, dolutegravir plus lamivudine; DTG + FTC/TAF, dolutegravir plus emtricitabine/tenofovir alafenamide; HIV, human immunodeficiency virus; IQR, interquartile range; MSM, men who have sex with men; pVL, plasma viral load.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
